Clinical improvement in psoriatic nail disease and psoriatic arthritis with tildrakizumab treatment

Dermatol Ther. 2020 Mar;33(2):e13216. doi: 10.1111/dth.13216. Epub 2020 Jan 8.

Authors

Fathima F Ismail¹, John May², John Moi³, Rodney Sinclair^{1

4

5}

Affiliations

¹ Sinclair Dermatology, East Melbourne, Victoria, Australia.
² University Hospital Geelong, Barwon Health, Geelong, Victoria, Australia.
³ The Royal Melbourne Hospital, Parkville, Victoria, Australia.
⁴ Department of Medicine, University of Melbourne, Melbourne, Victoria, Australia.
⁵ Epworth Healthcare, Richmond, Victoria, Australia.

PMID: 31899569
DOI: 10.1111/dth.13216

No abstract available

Publication types

Letter

MeSH terms

Antibodies, Monoclonal, Humanized
Arthritis, Psoriatic* / diagnosis
Arthritis, Psoriatic* / drug therapy
Humans
Nail Diseases* / diagnosis
Nail Diseases* / drug therapy
Nails
Psoriasis* / diagnosis
Psoriasis* / drug therapy

Substances

Antibodies, Monoclonal, Humanized
tildrakizumab